[
  {
    "ts": "2026-01-19T01:10:39+00:00",
    "headline": "What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative",
    "summary": "In recent weeks, Eli Lilly has deepened its push into AI-driven drug discovery and obesity care, including a planned US$1.00 billion co-innovation lab with NVIDIA, new AI collaborations such as Chai Discovery and TuneLab integrations, and positive Phase 3b data combining Taltz with Zepbound in psoriatic arthritis and obesity. At the same time, Strive Compounding Pharmacy’s federal antitrust lawsuit against Eli Lilly and Novo Nordisk over compounded GLP-1 access underscores growing legal and...",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-nvidia-ai-011039185.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6981af45-3e18-3efe-938c-cd2a9438b585",
      "content": {
        "id": "6981af45-3e18-3efe-938c-cd2a9438b585",
        "contentType": "STORY",
        "title": "What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative",
        "description": "",
        "summary": "In recent weeks, Eli Lilly has deepened its push into AI-driven drug discovery and obesity care, including a planned US$1.00 billion co-innovation lab with NVIDIA, new AI collaborations such as Chai Discovery and TuneLab integrations, and positive Phase 3b data combining Taltz with Zepbound in psoriatic arthritis and obesity. At the same time, Strive Compounding Pharmacy’s federal antitrust lawsuit against Eli Lilly and Novo Nordisk over compounded GLP-1 access underscores growing legal and...",
        "pubDate": "2026-01-19T01:10:39Z",
        "displayTime": "2026-01-19T01:10:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-nvidia-ai-011039185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-nvidia-ai-011039185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-19T09:30:00+00:00",
    "headline": "Prediction: 2026 Will Be the Year of Eli Lilly",
    "summary": "A catalyst lies just ahead.",
    "url": "https://www.fool.com/investing/2026/01/19/prediction-2026-will-be-the-year-of-eli-lilly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "3f129d2e-56ec-35d8-ba76-ca186fac1313",
      "content": {
        "id": "3f129d2e-56ec-35d8-ba76-ca186fac1313",
        "contentType": "STORY",
        "title": "Prediction: 2026 Will Be the Year of Eli Lilly",
        "description": "",
        "summary": "A catalyst lies just ahead.",
        "pubDate": "2026-01-19T09:30:00Z",
        "displayTime": "2026-01-19T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/72b3ba48760405ef96b4c96cdbf7cfd1",
          "originalWidth": 1400,
          "originalHeight": 924,
          "caption": "An investor smiles while leaning against a desk and looking at a tablet.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Au81nB0IWy4V64Oy6gmh.A--~B/aD05MjQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/72b3ba48760405ef96b4c96cdbf7cfd1.cf.webp",
              "width": 1400,
              "height": 924,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PTrjfqhQP3vvMZueHd_exg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/72b3ba48760405ef96b4c96cdbf7cfd1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/19/prediction-2026-will-be-the-year-of-eli-lilly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-2026-eli-lilly-093000965.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-19T09:19:15+00:00",
    "headline": "Where is NVIDIA Corporation (NVDA) Headed According to the Street?",
    "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the best strong buy growth stocks to buy according to hedge funds. NVIDIA Corporation (NASDAQ:NVDA) received a rating update from Jefferies on January 16, with the firm lifting the price target on the stock to $275 from $250 and maintaining a Buy rating on the shares. The firm told […]",
    "url": "https://finance.yahoo.com/news/where-nvidia-corporation-nvda-headed-091915918.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3454a9dd-d982-3b03-b56e-7a8578a9164f",
      "content": {
        "id": "3454a9dd-d982-3b03-b56e-7a8578a9164f",
        "contentType": "STORY",
        "title": "Where is NVIDIA Corporation (NVDA) Headed According to the Street?",
        "description": "",
        "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the best strong buy growth stocks to buy according to hedge funds. NVIDIA Corporation (NASDAQ:NVDA) received a rating update from Jefferies on January 16, with the firm lifting the price target on the stock to $275 from $250 and maintaining a Buy rating on the shares. The firm told […]",
        "pubDate": "2026-01-19T09:19:15Z",
        "displayTime": "2026-01-19T09:19:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Analyst Explains How NVIDIA (NVDA) Can Reach $8 Trillion Market Cap",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.ZnJY6aT_ZwW.CJaMIVd5g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qEoy5Rzsl1ePc1El_kU3KA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-nvidia-corporation-nvda-headed-091915918.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-nvidia-corporation-nvda-headed-091915918.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-19T12:50:03+00:00",
    "headline": "Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial. This study is the first controlled pharmacologic trial to evaluate the combined use of an incretin therapy, Zepbound (tirzepatide), alongside a […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-taltz-zepbound-combo-125003769.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5b8a99b2-88f5-32c0-acf9-e2c85405b605",
      "content": {
        "id": "5b8a99b2-88f5-32c0-acf9-e2c85405b605",
        "contentType": "STORY",
        "title": "Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial. This study is the first controlled pharmacologic trial to evaluate the combined use of an incretin therapy, Zepbound (tirzepatide), alongside a […]",
        "pubDate": "2026-01-19T12:50:03Z",
        "displayTime": "2026-01-19T12:50:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-taltz-zepbound-combo-125003769.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-taltz-zepbound-combo-125003769.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]